Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$16.75 USD

16.75
7,937,676

-0.35 (-2.05%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $16.77 +0.02 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Madeleine Johnson headshot

Sarepta Therapeutics (SRPT) Stock Surged 24% Today: Here's Why

by Madeleine Johnson

On Thursday, shares of Sarepta Therapeutics (SRPT) are surging, up almost 24% to $42.14 per share in morning trading after the biotech company reported second-quarter revenues that blew past expectations in its earnings report yesterday after the bell.

    Zacks Equity Research

    Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View

    by Zacks Equity Research

    Increase in Exondys 51 sales led Sarepta (SRPT) to post a narrower-than-expected loss in the second quarter of 2017.

      Zacks Equity Research

      Sarepta & BioMarin Settle Patent Litigation on Exon Skipping

      by Zacks Equity Research

      Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy therapies.

        Zacks Equity Research

        Mallinckrodt's MNK-1411 Gets Orphan Drug Status for DMD

        by Zacks Equity Research

        Mallinckrodt plc (MNK) announced that the FDA has granted orphan drug designation to its pipeline candidate - MNK-1411, which is being evaluated for the treatment of Duchenne muscular dystrophy (DMD).

          Zacks Equity Research

          Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017

          by Zacks Equity Research

          We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT) on Jun 28.

            Zacks Equity Research

            Sarepta Appoints Ex-Allergan Executive as CEO and President

            by Zacks Equity Research

            Sarepta Therapeutics, Inc. (SRPT) announced the appointment of Douglas S. Ingram as the new chief executive officer (CEO).

              Zacks Equity Research

              Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up

              by Zacks Equity Research

              Sarepta Therapeutics, Inc. (SRPT) reported narrower-than-expected loss in the first quarter of 2017. Meanwhile, the biotech company increased its 2017 sales outlook for Exondys 51 as patient and physician interest for the drug increased

                Zacks Equity Research

                Is the Options Market Predicting a Spike in Sarepta (SRPT) Stock?

                by Zacks Equity Research

                Investors in Sarepta Therapeutics, Inc. (SRPT) need to pay close attention to the stock based on moves in the options market lately.

                  Zacks Equity Research

                  Why Is Sarepta (SRPT) Down 2.7% Since the Last Earnings Report?

                  by Zacks Equity Research

                  Sarepta (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    Zacks Equity Research

                    Sarepta's DMD Drug Launch Slow; What's in Store for 2017?

                    by Zacks Equity Research

                    We issued an updated research report on Sarepta Therapeutics, Inc. (SRPT) on Mar 9, 2016.

                      Zacks Equity Research

                      Sarepta (SRPT) Q4 Loss Widens; Sales of Duchenne Drug Slow

                      by Zacks Equity Research

                      Sarepta Therapeutics, Inc. (SRPT) reported wider than expected loss in the fourth quarter of 2016.

                        Zacks Equity Research

                        Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options

                        by Zacks Equity Research

                        Options traders are pricing in a big move for Sarepta Therapeutics (SRPT) shares as it has huge implied volatility.

                          Zacks Equity Research

                          Is a Surprise Coming for Sarepta Therapeutics (SRPT) This Earnings Season?

                          by Zacks Equity Research

                          Sarepta Therapeutics is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                            Zacks Equity Research

                            Catabasis Hits 52-Week Low on Poor DMD Drug Study Data

                            by Zacks Equity Research

                            Catabasis (CATB) announced disappointing top-line safety and efficacy data from part B of the MoveDMD study (phase I/II) on edasalonexent (CAT-1004).

                              Zacks Equity Research

                              Is BioMarin (BMRN) Well Poised for Growth in 2017?

                              by Zacks Equity Research

                              We issued an updated research report on BioMarin Pharmaceutical Inc. (BMRN) on Jan 25.

                                Zacks Equity Research

                                Are Options Traders Betting on a Big Move in Sarepta Therapeutics (SRPT) Stock?

                                by Zacks Equity Research

                                Investors in Sarepta Therapeutics (SRPT) need to pay close attention to the stock based on moves in the options market lately.

                                  Zacks Equity Research

                                  Not Too Late to Ride on Q4 Earnings: 3 Biotech Picks

                                  by Zacks Equity Research

                                  The biotech sector continues to witness a flurry of mergers and acquisitions and licensing deals.